Last edition
News about " DCGI"
Akums Drugs and Pharmaceuticals introduces DCGI-approved Lasmiditan dispersible tablets, offering faster, patient-friendly migraine relief with improved compliance, especially for patients facing nausea and difficulty swallowing during acute attacks.
DCGI | 18/03/2026 | By News Bureau
Akums Becomes First Indian CDMO to Receive DCGI Approval for Innovative Glaucoma Treatment
Glaucoma ranks as the second leading cause of irreversible but preventable blindness worldwide, with India contributing to 23.5 percent of the global burden.
DCGI | 01/04/2025 | By Abha | 482
Aurobindo to launch HIV triple combination product for children living with HIV in low and middle-income countries under voluntary licence from ViiV Healthcare
DCGI | 17/08/2023 | By Sudeep Soparkar | 765
IPA Set to Host 8th Global Pharmaceutical Quality Summit, Focusing on 'Patient Centricity - A New Manufacturing and Quality Paradigm
DCGI | 14/06/2023 | By Sudeep Soparkar | 937
Covid vaccines for kids approved by DCGI
Covid vaccines for children above five years of age has been approved by the DCGI. The approval has been given to Covaxin, ZyCov-D, and Corbevax.
DCGI | 27/04/2022 | By Sudeep Soparkar | 978
A Synopsis Of Themis Medicare Viralex
Mumbai-based pharmaceutical company Themis Medicare?s anti-viral drug Viralex has received Drugs Controller General of India?s (DCGI) approval, the company informed the stock exchange on Monday
DCGI | 21/03/2022 | By Darshana | 717
Innovators need to feel confident, and regulators and innovators should not have any barriers during the process of new drug innovation, stated Drugs Controller General of India (DCGI), Dr V G Somani, during the session on creating regulatory ecosystem to support innovation at the Global Innovation Summit held by the Indian Pharmaceutical Alliance
DCGI | 21/11/2021 | By Darshana | 499
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy